Salivary Gland CancerNCT05390294
Survival With Patients Treated With Salivary Gland Cancer
An observational study of Salivary Gland Cancer and Salivary Gland Neoplasms, run by Clinical Center of Vojvodina at 1 site in Serbia.
Trial summary
Salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization. The aim of this study is to assess main clinical and pathological parameters related to patients survival Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Salivary Gland Cancer, Salivary Gland Neoplasms
- What is being tested?
- Surgical intervention with or without postoperative adjuvant therapy
- Type of treatment
- Surgery or procedure
- How many people
- 250 participants
- Where
- 1 siteSerbia
- Study dates
- 1 Jan 2022to 30 Apr 2022
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients treated due to SGC in the Clinic for maxillofacial surgery at Clinical center of Vojvodina
Who may be able to join
- Patients with salivary gland malignancies treted in the Clinic for maxillofacial surgery
Who cannot join
- Incomplete medical data Patients with metastatic tumord of salivary gland Patients with recurrent malignancies of salivary glands sent from other clinics
Trial locations and contacts
1 site in 1 country.
Serbia1 site
Clinic for maxillofacial surgery Clinical center of Vojvodina
Novi Sad, 11000
About this study
Official title: Prognostic Factors for Survival of Patients With Salivary Gland Malignancies
Salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization. The aim of this study is to assess main clinical and pathological parameters related to patients survival
Read the detailed description
The retrospective study enrolled medical charts of the patients treated due to salivaly gland cancers in the Clinic for maxillofacial surgery at Clinical center of Vojvodina in the period of 1. January 1996. to 31. December 2021. Patients demographics, type of the tumor, localization, TNM status and patohystological parameters were evaluated for patients survival and disease free periods
- Conditions
- Salivary Gland Cancer, Salivary Gland Neoplasms
- Being tested
- Surgical intervention with or without postoperative adjuvant therapy
- Keywords
- Salivary gland cancer, Survival, Prognostic factors
- Medical subject headings
- Salivary Gland Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Surgical intervention with or without postoperative adjuvant therapyProcedure or surgery
Surgical intervention with or without postoperative adjuvant therapy
| Study group | Role | What they receive |
|---|---|---|
| Patients free of the disease | Patients treated due to SGC without local recurrence or metastases Receives: Procedure: Surgical intervention with or without postoperative adjuvant therapy | |
| Patients with the disease | Patient with relapse of SGC, metastases or died due to SGC Receives: Procedure: Surgical intervention with or without postoperative adjuvant therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patients survival
Survival of patients treated due to SGC during observation period of minimum 2 years
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2022
- Study start1 Jan 2022
- Primary completion30 Mar 2022
- Study completion30 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Salivary Gland CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 250 participants (actual)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Clinical Center of Vojvodina
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Denis Brajković, Clinical Center of Vojvodina
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05390294
- Sponsor's protocol ID
- 1106012
- Status last verified
- May 2022
- First submitted
- 18 May 2022
- Last updated
- 25 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Factors for Survival of Patients With Salivary Gland Malignancies
- ClinicalTrials.gov ID
- NCT05390294
- Acronym / sponsor ID
- 1106012
- Conditions
- Salivary Gland Cancer, Salivary Gland Neoplasms
- Keywords
- Salivary gland cancer, Survival, Prognostic factors
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 250 participants (actual)
- Lead sponsor
- Clinical Center of VojvodinaUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 30 Mar 2022 (actual)
- Study completion
- 30 Apr 2022 (actual)
- First posted
- 25 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization. The aim of this study is to assess main clinical and pathological parameters related to patients survival
Detailed description
The retrospective study enrolled medical charts of the patients treated due to salivaly gland cancers in the Clinic for maxillofacial surgery at Clinical center of Vojvodina in the period of 1. January 1996. to 31. December 2021. Patients demographics, type of the tumor, localization, TNM status and patohystological parameters were evaluated for patients survival and disease free periods
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 5 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients free of the disease | – | Procedure: Surgical intervention with or without postoperative adjuvant therapyPatients treated due to SGC without local recurrence or metastases |
| Patients with the disease | – | Procedure: Surgical intervention with or without postoperative adjuvant therapyPatient with relapse of SGC, metastases or died due to SGC |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients treated due to SGC in the Clinic for maxillofacial surgery at Clinical center of Vojvodina
Key inclusion criteria (1 listed)
- Patients with salivary gland malignancies treted in the Clinic for maxillofacial surgery
Key exclusion criteria (1 listed)
- Incomplete medical data Patients with metastatic tumord of salivary gland Patients with recurrent malignancies of salivary glands sent from other clinics
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surgical intervention with or without postoperative adjuvant therapySurgical intervention with or without postoperative adjuvant therapy | Procedure or surgery | Patients free of the disease, Patients with the disease |
Primary outcome
Patients survival
Time frame: Through study completion, an average of 1 year
Survival of patients treated due to SGC during observation period of minimum 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 May 2022.
- Individual participant dataSharing planned: No
Related trials for Salivary Gland Cancer
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1/2
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
RecruitingPhase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Solid Tumors, HER2 Mutation
RecruitingObservational study
Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-Smokers
Oral Potentially Malignant Disorders, Oral Lichen Planus
Active, not recruitingPhase 2
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
Salivary Gland Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Salivary Gland Cancer and Salivary Gland Neoplasms, run by Clinical Center of Vojvodina at 1 site in Serbia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Serbia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patients survival (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2022.